VistaGen (NASDAQ: VTGN) is a clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (“CNS”) disorders. The company today announced it will host a conference call and webcast at 2:00 p.m. PT / 5:00 p.m. ET on Thursday, Aug. 11, 2022, to report financial results for its fiscal year 2023 first quarter ended June 30, 2022. Interested parties may join the call by dialing 1-888-999-5318 (U.S.) or 1-848-280-6460 (international) and entering conference ID: 4956626. Attendees may also visit https://ibn.fm/4ybuV to access an audio webcast of the conference call. In addition, as detailed in the announcement, a telephone playback of the call will be available after approximately 5:00 p.m. PT on Thursday, Aug. 11, 2022.
To view the full press release, visit https://ibn.fm/XuFtd
About VistaGen Therapeutics Inc.
VistaGen is a late clinical-stage biopharmaceutical company striving to transform the treatment landscape for individuals living with anxiety, depression and other CNS disorders. The company is advancing drug candidates with the potential to be faster-acting, and with fewer side effects and safety concerns, than those that are currently available. VistaGen’s clinical-stage candidates are targeting multiple forms of anxiety and depression. PH94B and PH10 belong to a new class of drugs known as pherine nasal sprays, which are investigational neuroactive steroids designed with a novel rapid-onset mechanism of action that activates chemosensory neurons in the nasal passages and can impact the olfactory-amygdala neural circuits without systemic uptake or direct activity on CNS neurons in the brain. VistaGen is passionate about transforming mental health care and redefining what is possible in the treatment of anxiety and depression. For more information, visit the company’s website at www.VistaGen.com.
NOTE TO INVESTORS: The latest news and updates relating to VTGN are available in the company’s newsroom at https://ibn.fm/VTGN
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.
As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.
For more information, please visit https://www.InvestorWire.com
InvestorWire is part of the InvestorBrandNetwork.